CTMX

CytomX Therapeutics, Inc.

1.47 USD
-0.01 (-0.68%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

CytomX Therapeutics, Inc. stock is down -3.92% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 February’s closed higher than January.

About CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the. treatment of breast cancer, head and neck squamous cell carcinoma, and diffuse large B-cell lymphoma.